Melanoma trials

AI-generated summary

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically is being studied. Conditions: Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth • Eligibility: Inclusion Criteria: * Adults ≥ 18 years of age. * Histologic proof of non-melanoma skin cancer. Patients with different skin tones based on the Fitzpatrick Scale, who present…. Goal: The primary objective of this study is the evaluation of the efficacy of the tissue oxygen imager based on PpIX DF in differentiating benign skin growth from non-melanoma skin cancer (NMSC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Dartmouth-Hitchcock Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors is being studied. Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +14 • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is considered surgically incurable with either: * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis…. Goal: This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anusha Kalbasi.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery is being studied. Conditions: Mucosal Melanoma, PD-L1 Positive • Eligibility: Inclusion Criteria: 1. Sign a written informed consent form (Informed Consent, ICF) and be able to comply with the visit schedule and related procedures outlined in the protocol.…. Goal: Melanoma has emerged as the fastest-growing malignancy in recent years, with incidence and mortality rates among both men and women in East Asian countries exceeding the Asian average. China ranks fifth among East Asian nations in melanoma incidence. Phase/Status/Sponsor: Unknown phase; RECRUITING; The First Hospital of Jilin University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials is being studied. Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS +9 • Eligibility: Inclusion Criteria: Patient must be ≥ 18 years and ≤ 39 years of age at registration. Patient must have a histologically confirmed diagnosis of primary cancer of any…. Goal: The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO. Phase/Status/Sponsor: Unknown phase; RECRUITING; Eastern Cooperative Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers is being studied. Conditions: Pancreatic Cancer, Renal Cell Cancer, Breast Cancer +2 • Eligibility: * INCLUSION CRITERIA: * For Phase I: Evaluable, unresectable cancer expressing CD70 as assessed by immunohistochemistry of resected tissue (greater than or equal to 2+ CD70 positive on…. Goal: Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is being studied. Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult +18 • Eligibility: Inclusion Criteria: * Patient must be ≥ 18yrs of age. * Patient must have the ability to understand, and the willingness to sign, a written informed consent form.…. Goal: This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b. Phase/Status/Sponsor: Unknown phase; RECRUITING; Neonc Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma is being studied. Conditions: Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma • Eligibility: Inclusion Criteria: * Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma. * The participant has an ECOG performance…. Goal: This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma Phase/Status/Sponsor: Unknown phase; RECRUITING; Iovance Biotherapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 is being studied. Conditions: Melanoma, Metastatic Melanoma, Advanced Solid Tumor +1 • Eligibility: Inclusion Criteria: Patients are eligible for inclusion in the study only if they meet all of the following criteria: 1. Patient has received at least 1 dose of…. Goal: This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Phase/Status/Sponsor: Unknown phase; RECRUITING; Replimune Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing is being studied. Conditions: Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer +7 • Eligibility: * INCLUSION CRITERIA: * Participants with a locally advanced or metastatic pathologically confirmed cancer whose NCI Licensed Independent Practitioner (LIP) determined they are candidates for treatment with atezolizumab,…. Goal: Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma is being studied. Conditions: Melanoma Metastatic, Uveal Melanoma, Metastatic, Mucosal Melanoma • Eligibility: Inclusion Criteria: * Able to provide written informed consent * \[68Ga\]Ga-A9T-3202 uptake in at least one measurable lesion (per RECIST v1.1) on PET scan * Histologically or cytologically…. Goal: The goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery. It will also see if this investigational drug can shrink melanoma tumors in the body. Phase/Status/Sponsor: Unknown phase; RECRUITING; Alpha-9 Oncology USA Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tebentafusp-tebn With LDT in Metastatic UM is being studied. Conditions: Metastatic Uveal Melanoma • Eligibility: Inclusion Criteria 1\. Age ≥18 years of age 2. Histologically or cytologically confirmed metastatic uveal melanoma in the liver. Patients must have at least one measurable liver metastasis…. Goal: This study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A\*0201 positive patients with metastatic uveal melanoma. In Part 1 of the study, the Prinicipal Investigator will investigate the safety and efficacy of tebentafusp-tebn in combination with hepatic IE in patients with a low to moderate hepatic disease burden. Phase/Status/Sponsor: Unknown phase; RECRUITING; Thomas Jefferson University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests GV20-0251 to see if it is safe in adults with advanced or refractory solid tumors. It is a single-center, single-arm early-stage trial at West China Hospital. It uses a 3+3 dose-escalation design, starting with 10 mg/kg and 20 mg/kg given every three weeks, to find a tolerable dose and watch for dose-limiting toxicities. The trial covers multiple solid tumor types to learn about safety and dosing across indications. Key exclusions include active infections, certain heart problems or QT prolongation, autoimmune disease needing immunosuppressive therapy, HIV/HBV/HCV infections, pregnancy, and recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma is being studied. Conditions: Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma +1 • Eligibility: Inclusion Criteria: Cohort 1: Must have a confirmed diagnosis of metastatic Uveal Melanoma. * Patients will be eligible regardless of the number of prior systemic therapies received. *…. Goal: This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma is being studied. Conditions: Advanced (Unresectable or Metastatic) Melanoma • Eligibility: Inclusion Criteria: 1. Age ≥18 years at the time of signing the informed consent (or adulthood where the legalage of majority in the country is established \>18 years).…. Goal: This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma Phase/Status/Sponsor: Unknown phase; RECRUITING; mAbxience Research S.L..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma is being studied. Conditions: Melanoma, Unresectable Melanoma • Eligibility: Inclusion Criteria: * Patients must have signed and dated an Institutional Review Board/Independent Ethics Committee -approved written informed consent form in accordance with regulatory and institutional guidelines. This…. Goal: This study will evaluate how safe the study drug is, how well patients tolerate it, how it works in the body, and the disease's response to the drug. The study drug being tested is sarilumab, when given with the combination of ipilimumab, nivolumab, and relatlimab in patients like yourself, with stage III or stage IV melanoma that cannot be removed by surgery. Phase/Status/Sponsor: Unknown phase; RECRUITING; NYU Langone Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers is being studied. Conditions: Skin Cancer, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin +3 • Eligibility: Inclusion Criteria: * Age ≥18 years. * Participants must meet at least one of the following criteria: * Finding suspicious of melanoma or non-melanoma skin cancer based on…. Goal: The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is: * Are blood based signatures able to predict progression-free survival (PFS)? Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Wisconsin, Madison.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body is being studied. Conditions: Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors • Eligibility: Key Inclusion Criteria: Dose escalation cohorts: 1. Histologically or cytologically confirmed diagnosis of solid malignancy (locally advanced or metastatic) with confirmed progression on standard-of-care therapy 2. Participants are…. Goal: This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is being studied. Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma +8 • Eligibility: Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing…. Goal: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Arizona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Personalised Immunotherapy Platform is being studied. Conditions: Melanoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma +2 • Eligibility: MELANOMA: Inclusion Criteria: 1. Written informed consent to participation for the use of tumour tissue, blood and stool and collection of standard clinical data. 2. Histologically confirmed resected…. Goal: This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours. The study will evaluate the documentation, processes, accuracy and utility of the predictive biomarker model in clinical practice. Phase/Status/Sponsor: Unknown phase; RECRUITING; Melanoma Institute Australia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma is being studied. Conditions: Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma +1 • Eligibility: Inclusion Criteria: * Confirmed unresectable and/or metastatic cutaneous melanoma. * 2 copies of the fully functional form of GPER protein-coding sequence. * Eligible for and willing to receive…. Goal: The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Phase/Status/Sponsor: Unknown phase; RECRUITING; Linnaeus Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NX-1607 in Adults With Advanced Malignancies is being studied. Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer +11 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received…. Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nurix Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) is being studied. Conditions: Uveal Melanoma • Eligibility: Inclusion Criteria: 1. Patient aged of 18 years or more. 2. Patient with uveal melanoma with high metastatic relapse risk defined as : * T2b/c/d ou ≥ T3,…. Goal: Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut Curie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Detection of Skin Tumors Using a Telemedicine Tool in Primary Care is being studied. Conditions: Skin Cancer Prevention, Melanoma In Situ, Skin Lesions +2 • Eligibility: Inclusion Criteria: * at least 1 suspected lession * phototype I or phototype II Exclusion Criteria: * skin lession examination by dermatologist in last 12 months * unsigned…. Goal: The project is a national, prospective, multicenter, single-arm interventional pilot of screening skin tumors in the Czech Republic. The primary aim of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of skin tumors by using a telemedicine tools and setting up and testing new methods and implementation into the system of social health care. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Institute of Health Information and Statistics of the Czech Republic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma is being studied. Conditions: Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation • Eligibility: Inclusion Criteria: * Age ≥ 18 years at the time of informed consent * Histologically confirmed diagnosis of melanoma. Any primary or unknown origin is permitted. * Melanoma…. Goal: The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer is being studied. Conditions: Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma +16 • Eligibility: Inclusion Criteria: * Age 18 or over * Histologically or cytologically documented advanced or metastatic cancer that has relapsed from or is refractory to standard treatment in two…. Goal: Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies is being studied. Conditions: Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma +1 • Eligibility: Key Inclusion Criteria: 1. Voluntary agreement to provide written informed consent prior to any study procedures and the willingness and ability to comply with all aspects of the…. Goal: This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Replimune Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Darovasertib in Primary Uveal Melanoma is being studied. Conditions: Uveal Melanoma • Eligibility: Inclusion Criteria: * Primary non-metastatic uveal melanoma * Able and willing to provide written, informed consent before initiation of any study-related procedures, and in the opinion of the…. Goal: This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10) Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Skin Cancer and Hyperthermia and Radiotherapy is being studied. Conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma Skin, Non-melanoma Skin Cancer • Eligibility: Inclusion Criteria: * Personally signed and dated written informed consent * Histologically confirmed invasive non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)…. Goal: The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Kantonsspital Winterthur KSW.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma is being studied. Conditions: Melanoma (Skin), Melanoma, Stage II, Stage I, Melanoma Stage +1 • Eligibility: Inclusion Criteria: * 18 years or older * Patients who have received a primary diagnosis of cutaneous melanoma stage I to II in the past 0-4 months Exclusion…. Goal: A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app. A total of hundred-eighty melanoma patients (stage I and II) will be randomised to receive either the SCP Melanoma app or usual care. Phase/Status/Sponsor: Unknown phase; RECRUITING; Erasmus Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients is being studied. Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer • Eligibility: Inclusion: 1. Age ≥18 years on day of signing informed consent. 2. Specific by tumor cohorts: a. For the HSNCC cohort, histologically confirmed diagnosis of advanced and/or metastatic…. Goal: This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Vyriad, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of DF6215 in Patients with Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Solid Tumor Cancer • Eligibility: Key Inclusion Criteria * Male or female patients ≥ 18 years old. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * An estimated life…. Goal: A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors; is designed to assess the safety, tolerability, and preliminary efficacy of DF6215 alone or in combination with pembrolizumab in patients with advanced solid tumors. The study is open-label, meaning both participants and investigators are aware of the treatment being administered. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dragonfly Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma is being studied. Conditions: Melanoma, Acral Melanoma, Temozolomide +4 • Eligibility: Inclusion Criteria: 1. age:18-75 years, male or female. 2. Histopathologically confirmed acral melanoma (stage Ⅱ/Ⅲ). 3. Has not received any systematic anti-tumor drug treatment. 4. Measurable disease based…. Goal: Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response. Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking University Cancer Hospital & Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma is being studied. Conditions: Metastatic Uveal Melanoma • Eligibility: Inclusion Criteria: * Patient is ≥18 years of age on the day of signing informed consent. * ECOG performance status of 0 or 1. * Histologically or cytologically…. Goal: This Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentafusp in patients with metastatic uveal melanoma (mUM) with isolated liver metastases. The rationale is that PHP enhances antigen release and immunomodulation, potentially sensitizing tumors to tebentafusp in HLA-A\*02:01-positive patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers is being studied. Conditions: Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC) • Eligibility: Inclusion Criteria: * Male or female subject aged ≥ 18 years. * Confirmed diagnosis of CLL or small lymphocytic leukemia (SLL) per iwCLL 2018 criteria. * History of…. Goal: This is a randomized, phase II, double-blind, placebo-controlled trial with planned crossover to the intervention arm after 1 year. Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Utah.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BostonGene and Exigent Genomic INsight Study is being studied. Conditions: Breast Cancer, Non-small Cell Lung Cancer, Melanoma +1 • Eligibility: Inclusion Criteria: * Patients must have a confirmed malignancy of: Locally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or;…. Goal: The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Phase/Status/Sponsor: Unknown phase; RECRUITING; BostonGene.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) is being studied. Conditions: Advanced or Metastatic NRAS-mutant Melanoma • Eligibility: Key Inclusion Criteria: 1. Willing and able to provide written informed consent 2. Age ≥ 18 years 3. Histologically or cytologically confirmed unresectable or metastatic cutaneous (includes acral)…. Goal: Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy). Phase/Status/Sponsor: Unknown phase; RECRUITING; Erasca, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma is being studied. Conditions: Malignant Melanoma • Eligibility: Inclusion Criteria: * At least 18 years of age. * Radical surgery for Cutaneous Malignant Melanoma (CMM) stage IIb-c and III. * Sufficient renal function for i.v. contrast…. Goal: It is not known whether radiological assessments during follow up after surgery for high risk melanoma improve survival. Since radiological examinations are resource demanding, could inflict worry and cause irradiation exposure it is an important question to address. Phase/Status/Sponsor: Unknown phase; RECRUITING; Uppsala University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer is being studied. Conditions: Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer +1 • Eligibility: Inclusion Criteria: 1. Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma or Stage III or IV NSCLC. 2. Participants who…. Goal: This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Iovance Biotherapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy is being studied. Conditions: Melanoma, Breast Cancer, Renal Cell Carcinoma +4 • Eligibility: Inclusion Criteria * Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included…. Goal: The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors is being studied. Conditions: Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm +13 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed non small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), melanoma, colorectal carcinoma (CRC) and triple-negative breast cancer (TNBC) solid tumor…. Goal: This phase I clinical trial tests the immune effects of fermented wheat germ in patients with advanced solid tumor cancers who are being treated with standard of care checkpoint inhibitors. Fermented wheat germ is a nutritional supplement that some claim is a "dietary food for special medical purposes for cancer patients" to support them in treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of California, Davis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy is being studied. Conditions: Metastatic Melanoma • Eligibility: Inclusion Criteria: * Age greater than or equal to 18 years, * Patient with advanced melanoma proved histologically, not BRAF mutated, BRAFV600 mutated and wild mutated, cutaneous or…. Goal: The objective of this study is to assess whether FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET-CT could be an early predictive method of therapeutic response to anti-PD-1 immunotherapy in metastatic melanoma after 2 cycles of ANTI-PD1. 20 patients will be enrolled and undergo three PET/CT scans: a baseline PET-CT, an early research PET-CT after 2 cycles of anti-PD1 (PET1) and a PET-CT at 3 months of initiation of treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Hospitalier Universitaire de Nice.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis is being studied. Conditions: Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III +4 • Eligibility: Inclusion Criteria: * Age ≥ 18 * Stage III/IV skin cancer * Treatment with CTLA-4 inhibitor alone or in combination with PD-1or PD-L1 blockade within the past 8…. Goal: The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin cancer. The main questions this study aims to answer are: * How many patients treated with infliximab experience steroid-free disease resolution after 7 weeks? Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) is being studied. Conditions: Melanoma Metastatic, Melanoma Recurrent, Cutaneous Melanoma +1 • Eligibility: Inclusion Criteria: * Patients with malignant melanoma (with confirmed histopathological diagnosis) stages III and IV not amenable to locoregional treatment or curative treatment * Measurable disease by RECIST…. Goal: The OTIMAS study is a phase II trial designed to evaluate if the duration of one year of pembrolizumab immunotherapy for advanced metastatic melanoma has equivalent efficacy as the two-year duration of historical controls. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Instituto do Cancer do Estado de São Paulo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II) is being studied. Conditions: Head and Neck Mucosal Melanomas • Eligibility: Inclusion Criteria: * Age 18 to 75 years, regardless of gender. * Histologically confirmed primary, resectable Head and Neck Mucosal Melanoma (HNMM), with measurable lesions (spiral CT scan…. Goal: This study aims to conduct a prospective clinical trial investigating the use of pucotenlimab in combination with lenvatinib and temozolomide as neoadjuvant and postoperative adjuvant therapy for resectable oral and head and neck mucosal melanoma. The primary objectives are to evaluate the safety and efficacy of this combination regimen in the neoadjuvant treatment of head and neck mucosal melanoma. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study of T3011 in Subjects With Advanced Melanoma is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: 1. Subjects with advanced melanoma; 2. At least one measurable lesion; 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; 4. Expected survival \>…. Goal: This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Pharmaceuticals Holding Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intratumoral N17350 in Advanced Solid Tumors is being studied. Conditions: Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin +4 • Eligibility: Inclusion Criteria: 1. Age ≥18 years (or legal age of consent in the study jurisdiction). 2. Able to provide written informed consent and willing/able to comply with study…. Goal: The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Onchilles Pharma Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Explorative Study on Addition of High-fiber Dried Chicory Root in Patients With an Intermediate to High-risk Cutaneous Melanoma. is being studied. Conditions: Melanoma, Stage II • Eligibility: Inclusion Criteria: * Age ≥18 years; * The participant understands the study and can provide written informed consent; * The participant received surgical treatment of an intermediate to…. Goal: Exploring the effect of supplementation with daily addition of prebiotic dried chicory root (WholeFiberTM) for 6 weeks on fecal SCFA levels, gut microbial composition and immune cell composition in minimal stage II A melanoma patients following surgical treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Medical Center Groningen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AMT-253 in Patients With Advanced Solid Tumours is being studied. Conditions: Malignant Melanoma, Advanced Solid Tumors • Eligibility: Inclusion Criteria: * 1\. Patients must be willing and able to understand and sign the ICF, and to adhere to the study visit schedule and other protocol requirements.…. Goal: This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion. Phase/Status/Sponsor: Unknown phase; RECRUITING; Multitude Therapeutics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS is being studied. Conditions: Melanoma, Atherosclerosis • Eligibility: Inclusion Criteria: * Capable of providing informed consent and willing to adhere to all protocol requirements * patients aged \> or equal to 40 years * Histologically confirmed…. Goal: This study is a prospective observational study evaluating the natural history of coronary plaque burden in participants with melanoma treated with ICI. The study will be conducted at various sites across Australia. Phase/Status/Sponsor: Unknown phase; RECRUITING; Monash University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors is being studied. Conditions: Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm +25 • Eligibility: Inclusion Criteria: * SCREENING: Patients with relapsed or refractory solid tumors and without known curative therapy or therapy proven to proven to prolong survival with acceptable quality of…. Goal: This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer \[NK\] cells) and how well they work when given together with cyclophosphamide and etoposide in treating children and young adults with solid tumors that have come back (relapsed) or that do not respond to treatment (refractory). NK cells, white blood cells important to the immune system, are donated/collected from cord blood collected at birth from healthy babies and grown in the lab. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy is being studied. Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma +7 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Body mass index (BMI) 18.5-40 kg/m\^2 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 4.…. Goal: This is a randomized, double-blind, fully controlled feeding study that will enroll melanoma patients starting standard-of-care ICB in three settings: adjuvant, neoadjuvant, and unresectable. Patients are randomized to the high fiber or healthy control diet. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery is being studied. Conditions: Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 +4 • Eligibility: Inclusion Criteria: * PRE-REGISTRATION- INCLUSION CRITERIA * Diagnosis of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy * At least one non-nodal lesion…. Goal: This phase I trial studies the best dose of ibrutinib when given together with pembrolizumab in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care is being studied. Conditions: NSCLC, Melanoma • Eligibility: Inclusion Criteria To participate in this study a participant must meet the eligibility of one of the following cohorts: Cohort 1: Cancers beginning initial treatment * One of…. Goal: Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma, and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by availability of tumor biopsy tissue for testing. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years at the time of informed consent 2. Patient must be able to provide informed consent. 3. Patient must have a histologically…. Goal: The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: To participate in the study, participants must meet all the following inclusion criteria: Cohort A only: 1. Prior treatment with anti-PD-(L)1 therapy (for example, pembrolizumab or…. Goal: This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Agenus Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. is being studied. Conditions: Metastatic (Stage IV) Melanoma • Eligibility: Inclusion Criteria: In order to participate in the trial, all patients must meet all the following criteria: 1. Patient must have signed the written informed consent prior to…. Goal: Although treatments for breast cancer have improved, 20-30% of patients with early disease develop metastases (cancer that spreads to other parts of the body). Among the different types of breast cancer, hormone-sensitive cancers that do not overexpress the HER2 protein (HR+/HER2-) are the most common. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors is being studied. Conditions: HNSCC, Melanoma, Gynecologic Cancer +3 • Eligibility: Inclusion Criteria * Participants must have signed and dated a current IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. Patients must have the…. Goal: The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies. The TIL selection process is based on evidence showing that CD8+ TIL which co-express both CD39 and CD103 harbor the bulk of tumor-reactivity and that the remaining CD8 TIL is mainly composed of non-tumor reactive bystander cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AgonOx, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab is being studied. Conditions: Melanoma Stage III, Melanoma Stage IV • Eligibility: Inclusion Criteria: 1. Written Informed Consent and HIPAA Authorization 1. Subjects must have the nature of the study explained to them. 2. Subjects must be willing and able…. Goal: Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Syntrix Biosystems, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma is being studied. Conditions: Refractory Melanoma • Eligibility: Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and avail-ability for the duration of the study…. Goal: The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded with antigens from the patient's tumor in the form of tumor lysate and mRNA. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Diakonos Oncology Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss is being studied. Conditions: Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma • Eligibility: Inclusion Criteria: 1. Be willing and able to provide written informed consent for the trial. 2. Be \>/= 18 years of age on day of signing informed consent.…. Goal: The goal of this clinical research study is to learn if GSK2636771 given in combination with pembrolizumab can help to control the disease in patients with refractory (has not responded to treatment) metastatic melanoma. The safety of this drug combination will also be studied. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ACT-TIL and ANV419 for Advanced Melanoma. is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: Patients who meet all the following criteria will be eligible to participate in the study: * Must provide written informed consent for the study. * Must…. Goal: In this study we aim to investigate safety and tolerability of tumor-infiltrating lymphocytes (TIL) adoptive cell therapy (ACT) incorporation in-vivo TIL expansion with ANV419 in patients with advanced melanoma Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University Hospital, Basel, Switzerland.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of IBI363 in Subjects with Advanced Solid Malignancies is being studied. Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer +1 • Eligibility: Inclusion Criteria: 1. Subjects have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this…. Goal: This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Innovent Biologics (Suzhou) Co. Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DermaSensor Postmarket Surveillance Study is being studied. Conditions: Melanoma, Skin • Eligibility: Inclusion Criteria: 1. Men or women of any ethnic group aged 40 and older 2. Primary skin lesion suspicious for melanoma 3. Patient is willing and able to…. Goal: The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; DermaSensor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease is being studied. Conditions: Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8 +7 • Eligibility: Inclusion Criteria: * Patients must have radiographic and/or CSF cytological evidence of LMD. For patient with melanoma: Must have a confirmed diagnosis of primary central nervous system (CNS)…. Goal: This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This pediatric MATCH trial tests tipifarnib in children and young people aged 12 months to 21 years whose advanced solid tumors, lymphoma, or histiocytic disorders have an HRAS gene alteration. - The main goal is to see how many patients have a tumor shrinkage or disappearance (objective response) with tipifarnib. - The study also looks at progression-free survival and how well the drug is tolerated in kids and teens. - It will explore biomarkers that might predict who responds and how tumor DNA in blood changes over time. - Key exclusions include pregnancy or breastfeeding, and not being eligible if you’re on other investigational drugs or certain interacting medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery is being studied. Conditions: Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7 +2 • Eligibility: Inclusion Criteria: * Patients must have unresectable stage III or stage IV melanoma, either initial presentation or recurrent, that is of cutaneous origin or unknown primary origin and…. Goal: This randomized phase II trial studies how well ipilimumab with or without high-dose recombinant interferon alpha-2b works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab, may block tumor growth by targeting certain cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery is being studied. Conditions: Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma +6 • Eligibility: Inclusion Criteria: * All sites of disease must be evaluated within 4 weeks prior to randomization; patients must have measurable disease as defined by Response Evaluation Criteria in…. Goal: This randomized phase II trial is studying how well giving ipilimumab with or without sargramostim (GM-CSF) works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery (unresectable). Ipilimumab works by activating the patient's immune system to fight cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma is being studied. Conditions: Melanoma; Renal Cell Carcinoma • Eligibility: Inclusion Criteria 1. ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization 3. Patients must have metastatic…. Goal: The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Indiana University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PHP and Immunotherapy in Metastasized UM is being studied. Conditions: Uveal Melanoma, Metastatic • Eligibility: Inclusion Criteria: 1. Age between 18-75 yrs 2. World Health Organization (WHO) Performance Status 0 or I 3. 50% or less histologically or cytologically confirmed unresectable metastatic uveal…. Goal: Melanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Leiden University Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer is being studied. Conditions: Skin Carcinoma • Eligibility: Inclusion Criteria: * Aged 19 to 79 years * Presenting with a lower limb wound following Mohs surgery for non-melanoma skin cancer, designated to heal by secondary intention…. Goal: This clinical trial studies whether a disposable negative pressure wound therapy (dNPWT) device, SNaP Wound Care System (Ultraportable Mechanically Powered Negative Pressure Wound Therapy) (SNaP), promotes wound healing in the lower limbs in patients that have undergone Mohs micrographic surgery (Mohs surgery) for non-melanoma skin cancer. Mohs surgery is a surgical technique used to treat skin cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is being studied. Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +13 • Eligibility: Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via…. Goal: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Have measurable disease per Response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) as assessed by the local site investigator. * Have an Eastern…. Goal: Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are types of cancer that may have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that are unlikely to be cured or controlled with currently available treatments. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bayer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) is being studied. Conditions: Advanced Melanoma, Renal Cell Carcinoma • Eligibility: Inclusion Criteria: * 1\. At least 1 site of disease must be accessible to provide repeat biopsies for tumor tissue. The biopsy may be waived if not feasible…. Goal: This study is a Phase 1, open-label, single institution, dose escalation and dose expansion study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma and RCC. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Yale University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Aerosolized Aldesleukin in Treating Patients With Lung Metastases is being studied. Conditions: Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma +5 • Eligibility: Inclusion Criteria: * Patients with diagnosis of advanced cancer with lung metastases; patients with no prior therapy are eligible if there is no known superior alternative medical therapy;…. Goal: This phase I/II trial studies the side effects and best dose of aerosolized aldesleukin and to see how well it works in treating patients with cancer that has spread from the original tumor to the lungs. Biological therapies, such as aerosolized aldesleukin, may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma is being studied. Conditions: Tumor, Metastatic Melanoma, Melanoma • Eligibility: Inclusion Criteria: 1. Male or female patients age ≥ 18 at the time of signing ICF 2. Patient has a pathologically confirmed diagnosis of metastatic melanoma that is…. Goal: The goal of this clinical research study is to find the recommended dose of OBX-115 in combination with acetazolamide that can be given to patients with metastatic melanoma previously treated with immune checkpoint inhibitors. The safety and tolerability of the study drug combination will also be studied. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma is being studied. Conditions: Advanced Malignant Solid Neoplasm, Recurrent Melanoma, Refractory Malignant Solid Neoplasm +5 • Eligibility: Inclusion Criteria: * Patients must have histologically proven solid tumors (Phase I) with biopsiable tumor (expansion cohort) refractory to standard therapy or for whom no standard therapy exists…. Goal: This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with riluzole in treating patients with solid tumors or melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Riluzole may stop or slow the growth of tumor cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of DXC014 in Patients With Advanced Solid Tumors. is being studied. Conditions: Small Cell Lung Cancer, Melanoma, Prostate Cancer +1 • Eligibility: Inclusion Criteria: 1. Voluntarily sign the informed consent form and comply with the protocol requirements. 2. Male or female. 3. For other solid tumor patients: Age ≥18 years…. Goal: This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Hangzhou DAC Biotechnology Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma is being studied. Conditions: Uveal Melanoma • Eligibility: Inclusion Criteria 1. Male or female participants age ≥ 18 years of age at the time of informed consent 2. Ability to provide and understand written informed consent…. Goal: To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Immunocore Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

eFLASH for Skin Lesions of Malignant Melanomas is being studied. Conditions: Metastatic Melanoma • Eligibility: Inclusion criteria 1. Signed study Informed Consent Form. 2. Males and females, age ≥ 18 years, no upper age limit. 3. Patients with metastatic melanoma and ≥ 1…. Goal: This prospective single center phase I trials aims to assess feasibility and safety of electron FLASH RT for treatment of melanoma skin metastases. Feasibility will be defined as FLASH delivery with an accuracy of +/-10% for each fraction, safety will be confirmed if a maximum of 2 out of 6 patients develop dose limited toxicity. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Zurich.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) is being studied. Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma +4 • Eligibility: Procurement Inclusion Criteria: 1. Evaluable neuroblastoma with persistent or relapsed disease 1. Recurrent disease following completion of aggressive multi-drug frontline therapy. 2. Progressive disease during aggressive multi-drug frontline…. Goal: This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy is being studied. Conditions: Triple Negative Breast Cancer, Uterine Cervical Cancer, Uterine Corpus Cancer +2 • Eligibility: Inclusion Criteria: 1. Pathologically confirmed diagnosis of clear cell renal cell carcinoma, melanoma, cervical cancer, endometrial cancer or triple negative breast cancer. 2. Patients nnot eligible for radical…. Goal: The aim of the study is to evaluate the response to four schemes of treatment with novel diagnostic tools - Immuno-PET and proteomics as well as standard imaging (magnetic resonsonce imaging and computed tomography). Two fractionation schedules of radiotherapy will be used. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Maria Sklodowska-Curie National Research Institute of Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors is being studied. Conditions: MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma +28 • Eligibility: Inclusion Criteria: 1. Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of PD1 mRNA high-expression…. Goal: This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SOLTI Breast Cancer Research Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA) is being studied. Conditions: Melanoma • Eligibility: INCLUSION CRITERIA: * Patient must be ≥ 18 years of age. * Patient must be a surgical candidate with Stage IIB, IIC melanoma or fully resectable Stage III…. Goal: This is a non-randomized experimental biomarker study evaluating ctDNA levels in patients with stage IIB/C and stage IIIB/C/D melanoma skin cancer pre and post-surgery Study participants will complete a ctDNA test within 4 weeks of their planned surgical resection of their melanoma. Within 4 weeks post-surgery another ctDNA test will be completed. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Utah.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Immunotherapy naive and without access to approved and/or available immune checkpoint inhibitor (ICI) therapy. * Measurable disease per RECIST v1.1. * One of the following…. Goal: This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma is being studied. Conditions: Melanoma Stage III or IV • Eligibility: Inclusion Criteria: * Written informed consent * Age 18 years or older * Confirmed diagnosis of melanoma * Stage IIB or IIC or stage III or stage IV…. Goal: People who develop a type of skin cancer known as 'melanoma' are often treated with immunotherapy. The type of immunotherapy used for patients with melanoma is known as Immune Checkpoint Inhibitors (ICI). Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Royal Marsden NHS Foundation Trust.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Investigation of the Performance of the Medical Device Dermalyser in Determining Melanoma Thickness Based on Dermoscopy Images is being studied. Conditions: Melanoma (Skin Cancer) • Eligibility: Inclusion Criteria: 1. Patient needs to be ≥18 years of age at inclusion 2. The patient has a suspected primary melanoma where surgery is planned 3. Willingness and…. Goal: In Sweden, approximately 9,000 Swedes are affected by melanoma annually, and each year, 500 individuals die from metastatic melanoma. The prognosis for melanoma primarily depends on the thickness of the tumor at diagnosis. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Vastra Gotaland Region.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients is being studied. Conditions: Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +2 • Eligibility: Inclusion Criteria: * Patient must be 18 to 75 years of age * Must have a confirmed diagnosis of Stage IIIB-D locally advanced or Stage IV melanoma (American…. Goal: This phase I/II trial tests the safety and side effects of LN-144 (Lifileucel) and pembrolizumab in treating patients with stage IIIB-D or stage IV melanoma that has spread to nearby tissue or lymph nodes. Biological therapies, such as LN-144 (Lifileucel), use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Richard Wu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

D-OCT for Detection and Subtyping of BCC: a Diagnostic Cohort Study is being studied. Conditions: Basal Cell Carcinoma, Optical Coherence Tomography • Eligibility: Inclusion Criteria: * 18+ years * Lesions suspect for non-melanoma skin cancer or premalignancy * Patient underwent D-OCT scan and biopsy conform regular care Exclusion Criteria: * Patient…. Goal: The current gold standard for diagnosing basal cell carcinoma (BCC) is the histopathological examination of biopsy specimen. However, non-invasive imaging modalities such as optical coherence tomography (OCT) may replace biopsy if BCC presence and its subtype can be established with high confidence. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Maastricht University Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors is being studied. Conditions: Cancer, Melanoma, Ovary Cancer +2 • Eligibility: Subjects must fulfill all the following inclusion criteria relevant to their tumor type to be eligible for participation in the study: Inclusion Criteria Malignant Melanoma * Histopathologically confirmed…. Goal: First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in combination with Pembrolizumab in solid tumors. The study is separated into two parts. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; ENB Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) is being studied. Conditions: Breast Cancer, Breast Neoplasms, Colon Cancer +5 • Eligibility: Inclusion Criteria: * Patients will have measurable and/or non-measurable disease, lacking curative options for whom the selected chemotherapy agents represent the standard of care * WHO performance status…. Goal: This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations is being studied. Conditions: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast • Eligibility: Inclusion Criteria: * Adults ≥18 years old. Other age restrictions may apply as per local regulations. * Unresectable and/or metastatic solid tumors with pre-specified HER2 mutations (S310F, S310Y,…. Goal: This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) +1 • Eligibility: Inclusion Criteria: * Must be ≥18 years of age * Must have histologically or cytologically confirmed diagnosis as follows: 1. Monotherapy Phase 1: A locally advanced unresectable or…. Goal: This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Immuneering Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: 1. Age ≥18 years at the time of signing the informed consent form; 2. Body weight 60 to 90 kg. 3. Histologically confirmed melanoma with the…. Goal: The aim of the study BCD-263-1 is to prove the comparability of the pharmacokinetics and similarity of the safety, immunogenicity and pharmacodynamic profiles of BCD-263 and Opdivo following intravenous administration to subjects with advanced unresectable or metastatic melanoma of the skin. The study will have randomized, double-blind design with parallel assignment. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Biocad.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma is being studied. Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma +9 • Eligibility: Inclusion Criteria: * Age \>= 18 years old * Histologically-confirmed primary uveal melanoma * Definitive local treatment for primary tumor, including surgical resection (enucleation) or radiation therapy (radioactive…. Goal: This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Sidney Kimmel Cancer Center at Thomas Jefferson University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests pembrolizumab in adults with advanced solid tumors to study gene changes and immune biomarkers during treatment and how they relate to response. Participants are adults 18 or older with unresectable or metastatic solid cancers that are incurable and for whom standard therapy has failed or isn’t available. Some eligible cancer types include head and neck squamous cell carcinoma, triple-negative breast cancer, epithelial ovarian cancer, and malignant melanoma. Exclusions include active infections or immune problems, active CNS metastases, autoimmune disease needing systemic treatment in the past two years, HIV or hepatitis B/C, pregnancy or breastfeeding, prior PD-1/PD-L1 therapy, and recent live vaccines or major cancer treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma is being studied. Conditions: Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8 • Eligibility: Inclusion Criteria: * Stage IIIB, IIIC, IIID histologically-proven melanoma. * Cancer confirmed to be surgically resectable, with surgery evaluation with planned prior to resection. * No prior immunotherapy…. Goal: This pilot phase I trial studies how well VX15/2503 (pepinemab) with or without ipilimumab and/or nivolumab work in treating participants with stage IIIB-D melanoma that can be removed by surgery. Monoclonal antibodies, such as VX15/2503, ipilimumab, and nivolumab may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Emory University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria: 1. Has or is willing to give consent to the…. Goal: The purpose of this Cohort Treatment Plan is to allow access to trametinib (monotherapy or in combination) and dabrafenib (monotherapy or in combination) for eligible patients diagnosed with metastatic melanoma BRAF mutation-positive. Phase/Status/Sponsor: Unknown phase; NO_LONGER_AVAILABLE; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer is being studied. Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor +19 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Signed informed consent and willing and able to comply with study procedures and scheduled visits. 3. For Dose Escalation,…. Goal: This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Salubris Biotherapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Had a negative sentinel lymph node biopsy * Participant has not been previously treated for melanoma * ECOG 0 or 1 * Participants must have…. Goal: The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Must have either metastatic melanoma and have not had previous treatment for their cancer, or resected melanoma and have had the cancer removed fully with…. Goal: The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Patients must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory and institutional…. Goal: This is a Phase II, open-label, single arm study. The study will consist of an assessment of the safety and tolerability of tocilizumab administered concurrently at 4 mg/kg every 6 weeks for 5 doses in combination with ipilimumab and nivolumab for four induction doses to week 12, then maintenance nivolumab alone up to one year to patients with advanced melanoma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; NYU Langone Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9 is being studied. Conditions: Acute Myeloid Leukemia, Melanoma, Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Diagnosis of acute myeloid leukemia (AML) and fit for allogeneic hematopoietic stem cell transplantation (alloHSCT), as assessed in the standard operating procedures. * Diagnosis of…. Goal: This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Turku University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma is being studied. Conditions: Uveal Melanoma • Eligibility: Inclusion Criteria: * Patients must suffer from melanoma of the uvea (stage T2, T3 and T4 \[AJCC TNM grading 2009\]). * Uveal melanoma must be resected and display…. Goal: Patients suffering from uveal melanoma (typed positive for monosomy 3 and without evidence for metastases) will be vaccinated over a period of 2 years with Dendritic Cell loaded with autologous Tumor RNA. 200 patients will be included. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital Erlangen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release is being studied. Conditions: Unresectable Melanoma, Metastatic Melanoma • Eligibility: Inclusion Criteria: 1. Eligible for treatment with AMTAGVI per United States Prescribing Information (USPI) 2. Have an AMTAGVI product manufactured for commercial treatment; however, the final manufactured product…. Goal: The objective of this expanded access protocol is to provide access to Out Of Specification (OOS) AMTAGVI treatment to patients. Phase/Status/Sponsor: Unknown phase; AVAILABLE; Iovance Biotherapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection is being studied. Conditions: Melanoma, Herpetic Infection • Eligibility: Inclusion Criteria: * Patient has provided written informed consent * Patient is an adult (≥ 18 years of age at the time of informed consent) with a diagnosis…. Goal: A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose. Phase/Status/Sponsor: Unknown phase; COMPLETED; Amgen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers is being studied. Conditions: Urothelial Carcinoma, Head and Neck Cancer, Melanoma +1 • Eligibility: Inclusion Criteria: 1. Subject is ≥18 to ≤75 years of age at the time of signing the study informed consent. 2. Subject has histologically confirmed diagnosis of any…. Goal: This Phase 1 study is designed as a cell dose escalation trial in HLA-A\*02:01 and HLA-A\*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors. The study will enroll subjects between the ages of 18 and 75 using a modified 3+3 cell dose escalation design, to evaluate dose limiting toxicities and determine the target cell dose range. Phase/Status/Sponsor: Unknown phase; COMPLETED; Adaptimmune.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Participants must have a metastatic melanoma diagnosis (stage IV) for which treatment with nivolumab or pembrolizumab, either alone or in combination with other therapies, is…. Goal: This study uses molecular imaging and novel immune monitoring to identify a biomarker of response for melanoma patients receiving immunotherapy with anti-PD-1 immunotherapy. Prior to treatment, FDG and FLT PET/CT will be obtained, together with blood and tumor biopsies from each patient. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Wisconsin, Madison.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Validation Study of an AI-based CAD System for Early Non-Invasive Detection of Cutaneous Melanoma is being studied. Conditions: Melanoma, Melanoma, Skin • Eligibility: Inclusion Criteria: * Patients with skin lesions with suspected malignancy * Age over 18 years old * Patients who consent to participate in the study by signing the…. Goal: The goal of this Cross-sectional analytical observational study of clinical case series is to validate a Computer-aided diagnosis software developed by AI Labs Group for the identification of cutaneous melanoma in images of lesions taken with a dermatoscopic camera. This study will be carried out in patients with skin lesions with suspected malignancy seen at the Dermatology Department of the Cruces University Hospital and Basurto University Hospital. Phase/Status/Sponsor: Unknown phase; COMPLETED; AI Labs Group S.L.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy is being studied. Conditions: Melanoma, Gastrointestinal Neoplasms, Genitourinary Cancer +2 • Eligibility: Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent 2. Diagnosed with non-small cell lung cancer (NSCLC) OR melanoma AND initiating therapy with single…. Goal: This research aims to identify clinical strategies to manage adverse events during immune checkpoint inhibitor therapy by (1) determining the impact of checkpoint inhibitors on metabolism through major CYP enzymes and (2) identifying associations between pro-inflammatory cytokine concentrations and negative clinical outcomes during checkpoint inhibitor therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Indiana University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma is being studied. Conditions: Metastatic Melanoma • Eligibility: Inclusion Criteria: * Patients must have unresectable metastatic stage IV melanoma or stage III in-transit or regional nodal disease. * Residual measurable disease after resection of target lesion(s)…. Goal: The overall purpose of this research study is to find a better way to treat melanoma. This will be a single arm exploratory trial to evaluate prospectively the feasibility of, the toxicities of, and the persistence of TIL which can survive in vivo. Phase/Status/Sponsor: Unknown phase; COMPLETED; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... is being studied. Conditions: Metastatic Melanoma, Skin Cancer • Eligibility: * INCLUSION CRITERIA: 1. Measurable metastatic melanoma with at least one lesion that is resectable for tumor infiltrating lymphocytes (TIL) generation. The lesion must be of at least…. Goal: Background: \- An experimental treatment for metastatic melanoma involves cell therapy, in which researchers take white blood cells (lymphocytes) from the tumor tissue, grow them in the laboratory in large numbers, and then use the cells to attack the tumor tissue. Before receiving the cells, chemotherapy is needed to temporarily suppress the immune system to improve the chances that the tumor-fighting cells will be able to survive in the body. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: 1. Be willing and able to give written informed consent for the study. 2. Be ≥ 18 years of age on day of informed consent. 3.…. Goal: This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma that have progressed on anti-PD-1-containing treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Highlight Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors is being studied. Conditions: Neoplasms, Melanoma • Eligibility: Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 2. For both the dose escalation and expansion cohort phases of the study, eligible participants must…. Goal: This study has 2 phases. The main aims of Phase 1b are: * to check for side effects from modakafusp alfa in adults with locally advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Teva Branded Pharmaceutical Products R&D LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether people with advanced solid tumors who have stable disease can stop PD-1/PD-L1 treatment after one year without harming outcomes. It is for patients being treated with PD-1/PD-L1 drugs (like pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab). Participants are randomly assigned to stop treatment after about one year or continue treatment until the cancer progresses, to learn the best length of therapy. To join, patients must have at least stable disease on scans within six weeks of randomization; those with progressive disease before randomization or immune-related toxicity that prevents staying on therapy beyond one year are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Patients aged 18 to 80 * Patients with unresectable or metastatic melanoma * Patients with ECOG performance of 0-2 * Patients able to provide written…. Goal: Recent studies suggest that patients with metastatic melanoma whose gut microbiome is colonized by eubiotic bacteria have a stronger anti-cancer response to anti CTLA-4 and anti PD1. The hypothesis of this research is that a pooled standardized fecal microbiome transfer (FMT) will shift melanoma patients' gut microbiome towards a composition close to that associated with a better response, and will therefore increase the response to a combination of anti CTLA-4 and anti PD1, without affecting the safety of these drugs. Phase/Status/Sponsor: Unknown phase; COMPLETED; Assistance Publique - Hôpitaux de Paris.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Unresectable stage III or stage IV melanoma which is histologically confirmed at the treating institution with KIT mutation(s) not known…. Goal: The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of [225Ac]-FPI-1434 Injection is being studied. Conditions: Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer +7 • Eligibility: Inclusion Criteria: 1. Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated,…. Goal: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent). Phase/Status/Sponsor: Unknown phase; TERMINATED; Fusion Pharmaceuticals Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: 1. Be willing and able to provide written informed consent/assent for the trial. 2. Histologically or cytologically confirmed malignant melanoma from skin, or mucosal melanoma (i.e.…. Goal: You are being asked to take part in this study because you have metastatic (cancer that has spread) melanoma. The goal of Part 1 of this clinical research study is to find the highest tolerable dose of APX005M that can be given with pembrolizumab that can be given to patients with metastatic melanoma. Phase/Status/Sponsor: Unknown phase; TERMINATED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether) is being studied. Conditions: Uveal Melanoma • Eligibility: Inclusion Criteria: 1. adult patients with metastatic UM; 2. no surgery or loco-regional treatment of metastases in a curative intent; 3. systemic treatment planned or started since less…. Goal: The study main objective is to assess whether the early introduction of supportive care demonstrates a benefit on patients' psychological care needs at 6 months (M6), versus oncological standard of care in patients with metastatic UM. Supportive care in patients with metastatic Uveal Melanoma (UM) Phase/Status/Sponsor: Unknown phase; COMPLETED; Institut Curie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma is being studied. Conditions: Metastatic Melanoma • Eligibility: Inclusion Criteria: * Signed and dated informed consent before any trial-related activities. * Male or female, between 18-75 years of age (both included). * Pathologically confirmed previously treated…. Goal: This is an open-label, phase 1, first-in-human (FIH), dose-escalation, multicenter, multinational trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy and in association with T-cell therapy with TILs in metastatic melanoma patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; TILT Biotherapeutics Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Be willing and able to provide written informed consent for the trial. * Be ≥ 18 years of age on day of signing informed consent.…. Goal: This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: * Pembrolizumab * AMG386 Phase/Status/Sponsor: Unknown phase; COMPLETED; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease is being studied. Conditions: Melanoma, Lymph Node Cancer • Eligibility: Inclusion Criteria: 1. Be willing and able to provide written informed consent for the study. 2. Be ≥ 18 years of age on day of signing informed consent.…. Goal: The purpose this research study is to determine if the combination of nivolumab and CMP-001 improves the likelihood of eradicating (destroying) disease in the lymph node (pathologic response rate). Phase/Status/Sponsor: Unknown phase; COMPLETED; Diwakar Davar.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease is being studied. Conditions: Ocular Melanoma • Eligibility: Inclusion Criteria Patients meeting all of the following criteria will be considered for admission to the trial: 1. Histologically proven ocular melanoma 2. Measurable disease according to RECIST…. Goal: This is an open-label, multi-center, single-arm clinical phase II study to further characterize the efficacy and safety of ipilimumab in patients with or without systemic pretreatment metastatic ocular melanoma. The DeCOG-MM-PAL11-Trial will be continued only for patients with ocular melanoma because sufficient numbers of cutaneous and mucosal melanoma patients have already been recruited. Phase/Status/Sponsor: Unknown phase; COMPLETED; Prof. Dr. med. Dirk Schadendorf.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sun Protection and Tanning Awareness in Rural Schools is being studied. Conditions: Melanoma, Adolescents • Eligibility: Inclusion Criteria: * Students are eligible if they are enrolled in a Utah high school (e.g. grades 9-12). Exclusion Criteria: * None. Goal: Drawing from prior school-based skin cancer prevention programs, we have adapted intervention materials to target rural high schoolers. Program components (including in-class education) will be co-implemented by the research team and participating school staff, with a focus on sustainability beyond the immediate study period. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Utah.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC) is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: 1. Male or female patients 18 years of age or older 2. Histologically proven malignant melanoma (Balch et al., J. Clin Oncol. 19(16): 3635-48, 2001) with…. Goal: The study is designed as a multicenter, double blind, parallel-group, placebo-controlled, randomized, event driven Phase II study of DTIC with or without bosentan as first-line treatment in patients with stage IV melanoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Actelion.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis is being studied. Conditions: Uveal Melanoma • Eligibility: Inclusion Criteria (main): * ECOG Performance Status of 0, 1 or 2 * Histologically or cytologically confirmed liver metastases of uveal melanoma * At least one measurable lesion…. Goal: Characterisation of effect of SIRT and DSM-TACE as local treatment options for liver metastases in patients with advanced uveal melanoma with respect to progression-free survival and exploratory comparison of secondary endpoints regarding application, activity, adverse effects and impact on quality of life in a randomized study design. Phase/Status/Sponsor: Unknown phase; COMPLETED; Charite University, Berlin, Germany.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study is being studied. Conditions: Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV • Eligibility: Inclusion Criteria: 1. Signed Written Informed Consent: patients must be willing and able to give written informed consent, that have to be given before starting of screening procedure.…. Goal: Title: Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic melanoma: a randomized "proof-of-principle" phase II study. Study Design: Randomized selection design, proof of principle study Study Duration: 36 months Number of Subjects: 24 evaluable patients Diagnosis and Main Inclusion Criteria: Patients with non resectable stage III or stage IV malignant melanoma carrying at least 2 measurable lesions, any line after 1st line Vemurafenib in patients carrying BRAF mutation-positive melanoma and/or ≥ 2nd line Ipilimumab. Phase/Status/Sponsor: Unknown phase; COMPLETED; Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies is being studied. Conditions: Cushing's Disease, Acromegaly, Neuroendocrine Tumors +6 • Eligibility: Inclusion Criteria: 1. Patient is currently participating in a Novartis-sponsored study receiving pasireotide (LAR and/or s.c.) on monotherapy or combination therapy (for Cushing's Disease or Acromegaly), and has…. Goal: The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator. Phase/Status/Sponsor: Unknown phase; COMPLETED; RECORDATI GROUP.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers is being studied. Conditions: Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers • Eligibility: Inclusion Criteria: * Life expectancy ≥ 3 months at recruitment * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at the time of study treatment initiation. *…. Goal: In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced non-melanoma skin cancers will receive a fixed dose of 0.1 mg of IFx-Hu2.0 intralesionally as monotherapy in up to three lesions at up to three time points. Subjects will be observed for any acute adverse events (AEs) post injection and for any delayed AEs at Day 28, 35 and/or 42 ± 7 days, depending on the cohort (exposure escalation and expansion design). Phase/Status/Sponsor: Unknown phase; COMPLETED; TuHURA Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma is being studied. Conditions: Metastatic Melanoma • Eligibility: Inclusion Criteria: * Men and women aged ≥ 18 years of age. * Patient with metastatic or unresectable melanoma * Nivolumab or Nivolumab + Ipilimumab treatment indication *…. Goal: This is an open bi-centric prospective non-randomized study in patients with metastatic melanoma treated with a first line treatment of Nivolumab +/- Ipilimumab. The aim of the study is to characterize the immune cells modulations under anti-PD-1 +/- anti-CTLA4 and identify the differences between responder and non-responder patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hospices Civils de Lyon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous +6 • Eligibility: Key Inclusion Criteria: * Part A: Histologically confirmed advanced/metastatic castration-resistant prostate adenocarcinoma, epithelial ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, melanoma,…. Goal: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma is being studied. Conditions: Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain • Eligibility: Inclusion Criteria: 1. Patient age is \>= 18 years 2. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1. 3. Ability to provide…. Goal: This phase I trial studies the side effects and best dose of ipilimumab when given together with whole brain radiation therapy or stereotactic radiosurgery in treating patients with melanoma with brain metastases. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sidney Kimmel Cancer Center at Thomas Jefferson University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible…. Goal: This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Actym Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of IK-595 in RAS- or RAF-altered Advanced Tumors is being studied. Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: 1. Patients ≥ 18 years of age. 2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 3. Adequate organ function as…. Goal: This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit. Phase/Status/Sponsor: Unknown phase; TERMINATED; Ikena Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer is being studied. Conditions: Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative +64 • Eligibility: Inclusion Criteria: * Newly diagnosed patients for the following conditions * Colon cancer stage III and IV * Rectal cancer stage II, III, IV * Glioblastoma multiforme (brain)…. Goal: This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management. Phase/Status/Sponsor: Unknown phase; COMPLETED; Stanford University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma is being studied. Conditions: Malignant Melanoma • Eligibility: Inclusion Criteria: 1. Male or female patients at least 18 years of age at the time of signing the ICF. 2. Histologically confirmed diagnosis of unresectable stage IIIB…. Goal: This is a randomized, open label study to investigate efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as first line treatment of adult patients with histologically confirmed unresectable metastatic melanoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Ultimovacs ASA.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2 is being studied. Conditions: Metastatic Renal Cell Cancer, Malignant Melanoma, Metastatic • Eligibility: Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed non resectable stage III or IV advanced melanoma or Renal Cell Carcinoma (RCC). 2. Patients must have a…. Goal: Title: Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response Phase: Proof of Principle phase II study Study Design: Single center, open-label trial to assess the immune response and potential biomarkers predictive of response Study Duration: Total duration: 36 months Enrollment: 20 months Treatment: 5 months per patient Follow-up every three months Number of Subjects: Mini-max two-stage Simon design: • Step 1: 7 patients enrolled If tumor antigen-specific immune response is observed in at least 3 patients: • Step 2: recruitment of an additional 12 patients Phase/Status/Sponsor: Unknown phase; COMPLETED; Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Must have been diagnosed with either Stage IIIA (\> 1 mm tumor in lymph node)/B/C/D or Stage IV melanoma by American Joint Committee on Cancer…. Goal: The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma. Phase/Status/Sponsor: Unknown phase; TERMINATED; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy is being studied. Conditions: Prostate Cancer, Breast Cancer, Lung Cancer +1 • Eligibility: Inclusion Criteria: * Hormone Refractory, Metastatic Prostate Cancer, Lung Cancer, and Melanoma or Breast Cancer Exclusion Criteria: -Life expectancy of less than 3 months. Goal: Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and systemic antitumoral immune responses. Several mechanisms of tumor immune evasion have been identified, including low intratumor expression of antigens and elevated expression of inhibitory co-regulatory molecules. Phase/Status/Sponsor: Unknown phase; COMPLETED; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: * Participants in the advanced melanoma cohort * Participants included in the cohort by Flatiron criteria of: cutaneous melanoma with pathologic stages III or IV, either…. Goal: The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy Phase/Status/Sponsor: Unknown phase; COMPLETED; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

RTA 408 Capsules in Patients With Melanoma - REVEAL is being studied. Conditions: Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma • Eligibility: Inclusion Criteria: 1. Be ≥18 years of age; 2. Have advanced, unresectable (Stage III) or metastatic (Stage IV) melanoma; 3. Be eligible for commercial receipt of therapy to…. Goal: Malignant melanoma is a leading cause of death from cutaneous malignancies, accounting for approximately three-fourths of all skin cancer deaths. For metastatic or unresectable melanomas, standard treatment options include immune checkpoint inhibitors (e.g., ipilimumab and nivolumab) and other therapies, however, approved therapies are rarely curative. Phase/Status/Sponsor: Unknown phase; COMPLETED; Biogen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma (AJCC Stage IIIB, IIIC, or IV) * Presence of BRAF V600E or…. Goal: This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized. Phase/Status/Sponsor: Unknown phase; COMPLETED; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma is being studied. Conditions: Metastatic NRAS Melanoma • Eligibility: Inclusion Criteria: 1. Histologically confirmed metastatic or locally advanced unresectable malignant melanoma with an activating NRAS mutation. 2. Available archival tissue, or if not, the patient is willing…. Goal: Patients with metastatic Neuroblastoma RAS (NRAS) melanoma are currently treated with first line immune checkpoint inhibitors (nivolumab, pembrolizumab). Thus far, no targeted therapy has been approved in NRAS mutated melanoma as a second line treatment, because although the use of a MEK inhibitor (binimetinib) alone was superior to the gold standard chemotherapy (dacarbazine) in a phase 3 trial, the progression free survival gain was very modest. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hospices Civils de Lyon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma is being studied. Conditions: Uveal Melanoma • Eligibility: Inclusion Criteria: * Advanced or unresectable melanoma of presumed uveal origin. Non-uveal melanomas with "malignant blue nevus" physiology with GNAQ, GNA11, CYSLTR2, or PLCB4 driver alterations are eligible…. Goal: This study is measuring the safety of the study drug, ADI-PEG 20, combined with immunotherapy drugs nivolumab and ipilimumab in treating patients with advanced uveal melanoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of SEA-CD40 Given With Other Drugs in Cancers is being studied. Conditions: Melanoma, Carcinoma, Non-Small- Cell Lung • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed unresectable malignancy defined as one of the following: * Cohort 1: Relapsed and/or refractory metastatic melanoma * Uveal/ocular melanoma is excluded…. Goal: This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. Phase/Status/Sponsor: Unknown phase; COMPLETED; Seagen Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors is being studied. Conditions: Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma +6 • Eligibility: Key Inclusion Criteria: * Have a histologically or pathologically documented, locally-advanced or metastatic solid tumor for which standard curative measures do not exist or are no longer effective…. Goal: To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01). Phase/Status/Sponsor: Unknown phase; TERMINATED; Turnstone Biologics, Corp..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy is being studied. Conditions: Metastatic Melanoma, Advanced Melanoma • Eligibility: Inclusion Criteria: 1. Participants must have a histologically or cytologically confirmed advanced/metastatic melanoma by pathology report. Participants with cutaneous, mucosal, acral and unknown primaries will be allowed. 2.…. Goal: This is a first-in-human, multi-center, multi-cohort, open-label, phase Ib/II study of XmAb22841 (CTLA-4 X LAG3) administered in combination with XmAb23104 (PD1 X ICOS) in participants with a histologically or cytologically confirmed diagnosis of an advanced/metastatic melanoma. XmAb22841 (CTLA-4 X LAG3) is a bi-specific antibody targeting two different T cell membrane proteins responsible for regulation of T cell activity. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia is being studied. Conditions: Melanoma • Eligibility: For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Adults with a primary diagnosis of melanoma with involvement of lymph nodes or…. Goal: This study is designed to estimate the effectiveness of nivolumab when given to participants after removing their cancer with surgery, over a 5-year follow-up, in real-world conditions in Australia. Phase/Status/Sponsor: Unknown phase; COMPLETED; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.